Myeloproliferative Neoplasms to Consider with Splenomegaly
Primary myelofibrosis (PMF) is the myeloproliferative neoplasm most strongly associated with splenomegaly and should be the primary diagnostic consideration, as palpable splenomegaly is a minor diagnostic criterion for both pre-PMF and overt PMF according to WHO 2016 criteria 1.
Diagnostic Approach by Splenomegaly Severity
Massive Splenomegaly
When encountering massive splenomegaly, prioritize PMF in your differential. According to WHO 2016 diagnostic criteria, palpable splenomegaly is explicitly listed as one of the minor criteria required for PMF diagnosis 1. The pathophysiology involves splenic extramedullary hematopoiesis driven by CXCL12/CXCR4 pathway alterations that cause hematopoietic stem cell migration from bone marrow to spleen 2.
Moderate Splenomegaly
Consider all three Philadelphia chromosome-negative MPNs:
- Polycythemia vera (PV): Splenomegaly occurs but is not a diagnostic criterion. Look for hemoglobin >16.5 g/dL (men) or >16 g/dL (women), JAK2 mutation positivity (>95% of cases), and subnormal erythropoietin levels 1.
- Essential thrombocythemia (ET): Splenomegaly is less prominent. Diagnostic focus is platelet count ≥450 × 10⁹/L with JAK2, CALR, or MPL mutations 1.
Progressive Splenomegaly in Known MPN
Increasing splenomegaly (≥5 cm increase from left costal margin or newly palpable) is a diagnostic criterion for post-PV myelofibrosis (PPV-MF) and post-ET myelofibrosis (PET-MF), indicating disease transformation 3.
Key Diagnostic Features for PMF
For overt PMF diagnosis, you need all three major criteria plus at least one minor criterion 1:
Major Criteria:
- Megakaryocyte proliferation with atypia plus reticulin/collagen fibrosis grade 2-3
- Exclusion of BCR-ABL1+ CML, PV, ET, MDS, or other myeloid neoplasms
- JAK2, CALR, or MPL mutation (or other clonal marker if triple-negative)
Minor Criteria (need ≥1):
- Anemia not from comorbidity
- Palpable splenomegaly
- Leukocytosis ≥11 × 10⁹/L
- Elevated LDH
- Leukoerythroblastosis
Molecular Testing Strategy
Order JAK2V617F testing first (present in ~60% of PMF cases), followed by CALR mutations (60-80% of JAK2/MPL-negative cases), then MPL mutations (5-8% of PMF) 3. This sequential approach identifies 85-90% of PMF patients. The remaining 10-15% are "triple-negative" but may have other clonal markers 3.
Clinical Phenotype Recognition
PMF presents with two distinct phenotypes that influence splenomegaly severity 4:
- Myeloproliferative phenotype: Progressive massive splenomegaly, normal/mildly decreased hemoglobin, higher JAK2V617F burden, associated with secondary MF
- Myelodepletive phenotype: Modest splenomegaly, ≥2 cytopenias, primary MF, lower JAK2V617F burden, higher genomic complexity
Critical Pitfall
Do not diagnose Banti syndrome or other non-malignant causes of splenomegaly without first excluding CML and other MPNs through complete blood count with differential and molecular testing 5. Massive splenomegaly can mask underlying leukocytosis, and premature splenectomy without proper hematologic workup may delay appropriate targeted therapy.
Confirmatory Imaging
While physical examination detects splenomegaly, MRI or CT provides objective spleen volume measurement (normal <300 mL). Ultrasonography correlates strongly with MRI (r=0.96) and is acceptable for serial monitoring in clinical practice 6.